Online inquiry

IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ469MR)

This product GTTS-WQ469MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ469MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11360MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ6558MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ12939MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ2639MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ10727MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ5959MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ12022MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ6018MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW